Zusammenfassung
Die Verschreibung von Inhalativa durch den Arzt erfolgt nicht nur unter pharmakologischen Gesichtspunkten, sondern unter besonderer Berücksichtigung physikalischer Eigenschaften des Inhalationssystems, der speziellen und dosisrelevanten Galenik sowie der individuellen Krankheitssituation bzw. auch der intellektuellen und manuellen Fähigkeiten des Patienten. Die korrekte Handhabung der Systeme muss intensiv geschult und überprüft werden. Dies ist auch in den Disease Management Programmen (DMP) Asthma und COPD so verankert. Ein Austausch von Inhalationssystemen ohne Berücksichtigung der oben genannten Kriterien und ohne erneute Schulung widerspricht allen Empfehlungen nationaler und internationaler Fachgesellschaften und gefährdet die betroffenen Patienten.
Abstract
The prescription of an inhalative therapy by the physician is not only based on pharmacological aspects, but also on the physical characteristics of the inhalation device, the special and dose-relevant galenics as well as on the patient’s individual situation, e. g. disease severity, the intellectual and manual skills. The correct use of the various devices has to be trained and controlled. This approach is also fixed in the Disease Management Programmes (DMP) for asthma and COPD. The substitution of inhalation devices without consideration of the above-mentioned criteria and without retraining is contradictory to all recommendations of national and international respiratory societies and may put the patients at risk.
Literatur
1
Global Burden of Disease Study.
Lancet.
1997;
149
1263
2 Fabel H, Konietzko N. Weißbuch Lunge. Stuttgart: Thieme 2005
3
Dennis J H, Hendrick D J.
Design characteristics for drug nebulizers.
J Med Eng Technol.
1992;
16
63-68
4
Newhouse M T.
Aerosolerzeugung und Verteilungssysteme zur pulmonalen Medikamentenapplikation: Theorie und Praxis.
Innere Medizin.
1993;
48
363-368
5
Sakula A.
A history of asthma.
J R Coll Physicians Lond.
1988;
22
36-44
6
Aerosol Consensus Statement.
Chest.
1991;
100
1106-1109
7
Morrow-Brown H, Storey G, George W HS.
Beclomethasone dipropionate: a new steroid aerosol for the treatment of allergic asthma.
BMJ.
1972;
2
585-590
8
Visser J.
Van der Waals and other cohesive forces affecting powder fluidization.
Powder Technol.
1989;
58
1-10
9
Webb J, Rees J, Clark T J.
A comparison of the effects of different methods of administration of beta 2 sympathomimetics in patients with asthma.
Br J Dis Chest.
1982;
76
351-357
10
Boe J, Dennis J H.
European respiratory society nebulizer guidelines: technical aspects.
Eur Respir Rev.
2000;
10
1-237 (Rev. 72)
11
British Thoracic Society, National Asthma Campaign, Royal College of Physicians of London .
The British guidelines on asthma management: 1995 review and position statement.
Thorax.
1997;
52
S11
12
Byron P R.
Pulmonary targeting with aerosols.
Pharm Technol.
1987;
5
42-54
13
Byron P R, Patton J S.
Drug delivery via the respiratory tract.
J Aerosol Med.
1994;
7
49-75
14 Everard M L, Dolovich M. In vivo measurements of lung dose. In: Risgaard M, O'Callaghan C, Smaldone G (Hrsg). Drug delivery in the lung: clinical aspects. Lung biology in health and disease. New York: Marcel Dekker 2000
15 Heyder J. Deponierung von Aerosolteilchen im Atemtrakt des Menschen. In: Scheuch G. Aerosole in der Inhalationstherapie. München: Dustri 1997: 1-10
16
Köhler D, Fleischer W, Matthys H.
Depositionsmuster von Dosieraerosolen im menschlichen Organismus.
Atemw Lungenkrkh.
1985;
11
340-341
17 Köhler D, Fleischer W. Theorie und Praxis der Inhalationstherapie. München: Arcis 2000
18
Smith K J, Chan H K, Brown K F.
Influence of flow rate on aerosol particle size distributions from pressurized and breath-actuated inhalers.
J Aerosol Med.
1998;
11
231-245
19 Dalby R N, Tiano S L, Hickey A J. Medical devices for the delivery of therapeutic aerosols to the lung. In: Hichey AJ (Hrsg). Inhalation Aerosols: Physical and Biological Basis for Therapy. New York: Marcel Dekker 1996: 441-474
20 Hickey A J, Evans R M. Aerosol generation from propellant-driven MDIs. In: Hichey AJ (Hrsg). Inhalation Aerosols: Physical and Biological Basis for Therapy. New York: Marcel Dekker 1996: 417-440
21
Ad Hoc Committee on Health Literacy for the Council of Scientific Affairs, American Medical Association, Health Literacy .
Report of the Council of Scientific Affairs.
JAMA.
1999;
281
552-557
22
Armitage J M, Williams S J.
Inhaler technique in the elderly.
Age and Ageing.
1988;
17
275-278
23
Crompton G.
Problems patients have using pressurized aerosol inhalers.
Eur J Respir Dis.
1982;
63
101-104
24
Friegang B.
New method of beclometasone aerosol administration to children under 4 years of age.
Can Med Assoc J.
1977;
117
1308-1309
25
Petro W, Gebert P, Lauber B.
Ursachen fehlerhafter Anwendung von Dosieraerosolen.
Pneumologie.
1994;
48
191-196
26
Saunders K B.
Misuse of inhaled bronchodilator agents.
BMJ.
1965;
1
1037-1038
27
Giraud V, Roche N.
Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability.
Eur Respir J.
2002;
19
246-251
28
Bronsky E A, Debelic M, Pujet J C. et al .
Ease-of-use study of pirbuterol acetate in the Autohaler actuator in three countries: the United States, Germany, and France.
J Asthma.
1993;
30
439-443
29
Chapman K R, Love L, Brubaker H.
A comparison of breath-actuated and conventional metered-dose inhaler inhalation techniques in elderly subjects.
Chest.
1993;
104
1332-1337
30
Fergusson R J, Lenney J, McHardy G JR. et al .
The use of the Autohaler® device by patients with severe airflow obstruction.
Eur Resp J.
1991;
4
172-174
31
Goodman D E, Israel E, Rosenberg M. et al .
The influence of age, diagnosis, and gender on proper use of metered-dose inhalers.
Am J Respir Crit Care Med.
1994;
150
1256-1261
32
Larsen J S, Hahn M, Ekholm B. et al .
Evaluation of conventional press-and-breathe metered-dose inhaler technique in 501 patients.
J Asthma.
1994;
31
193-199
33
Marshik P L.
A novel breath actuated device (Autohaler®) consistently actuates during the early phase of inspiration.
J Aerosol Med.
1995;
8
187-195
34
Newman S P, Weisz A WB, Talaee N. et al .
Improvement of drug delivery with a breath actuated pressurized aerosol for patients with poor inhaler technique.
Thorax.
1991;
46
712-716
35
Brown P H, Ning A CWS, Greening A P. et al .
Peak inspiratory flow through Turbohaler® in acute asthma.
Eur Respir J.
1995;
8
1940-1941
36
Dewsbury N J, Kenyon C J, Newman S P.
The effect of handling techniques on electrostatic charge on spacer devices: a correlation with in vivo particle size analysis.
Int J Parm.
1996;
137
216-264
37
Janssens H M, Devadason S G, Hop W CJ.
Variability of aerosol delivery via spacer devices in young children in daily life.
Eur Respir J.
1999;
13
787-791
38
Newman S A, Morén F, Pavia D. et al .
Deposition of pressurized suspension aerosols inhaled through extension devices.
Am Rev Respir Dis.
1991;
124
17-20
39
Newman S P, Millar A B, Lennard-Jones T R. et al .
Improvement of pressurized aerosol deposition with the nebuhaler spacer device.
Thorax.
1984;
39
935-941
40
Barry P, O'Callaghan C.
Poor output of salbutamol from a spacer device – the effect of spacer static charge and multiple actuations.
Thorax.
1994;
49
402
41
Barry P, O'Callaghan C.
Multiple actuations of salbutamol MDI into a spacer device reduce the amount of drug recovered in the respirable range.
Eur Respir J.
1994;
7
1707-1709
42
Bouchikhi A, Becquemin M H, Bignon J. et al .
Particle size study of nine metered dose inhalers, and their deposition probabilities in the airways.
Eur Respir J.
1988;
1
547-552
43
Leach C L, Davidson P J, Boudreau R J.
Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone.
Eur Respir J.
1998;
12
1346-1353
44
Tansey I.
The technical transition to CFC-free inhalers.
Br J Clin Pract Suppl.
1997;
89
22-27
45
Aubier M, Wettengel R, Gans S JM.
Efficacy of HFA-beclomethasone dipropionate extra-fine aerosol (800 µg/day) versus HFA-fluticasone propionate (1000 µg/day) in patients with asthma.
Respiratory Medicine.
2001;
95
212-220
46
Dahl R, Ringdal N, Ward S M. et al .
Equivalence of asthma control with new CFC-free formulation HFA-134a beclomethasone dipropionate and CFC-beclomethasone dipropionate.
Br J Clin Pract.
1997;
51
11-15
47
Gross G, Thompson P J, Chervinsky P. et al .
Hydrofluoroalkane-134a beclomethasone dipropionate, 400 µg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 µg, for the treatment of moderate asthma.
Chest.
1999;
115
343-351
48
Juniper E F, Buist A S.
Health-related quality of life in moderate asthma: 400 µg hydrofluoroalkane beclomethasone dipropionate vs 800 µg chlorofluorocarbon beclomethasone dipropionate. The Study Group.
Chest.
1999;
116
1297-1303
49
Magnussen H.
Equivalent asthma control after dose reduction with HFA-134a beclomethasone solution aerosol. Comparative Inhaled Steroid Investigation Group (CISIG).
Respir Med.
2000;
94
549-555
50
Worth H, Muir J F, Pieters W R.
Comparison of hydrofluoroalkane-beclomethasone dipropionate Autohaler with budesonide Turbuhaler in asthma control.
Respiration.
2001;
68
517-526
51
Frieß S, Kutz G.
Pulverinhalatoren: vom feindispersen System zum fertigen Arzneimittel.
Dtsch Apoth Ztg.
1993;
133
1242-1245
52
Hickey A J, Concessio N M, Oort M M van. et al .
Factors influencing the dispersion of dry powders as aerosols.
Pharm Tech.
1994;
8
58-82
53
Brown P H, Blundell G, Greening A P. et al .
Do large spacer devices reduce the systemic effects of high dose inhaled corticosteroids?.
Thorax.
1990;
45
736-739
54
Clark A R, Hollingworth A M.
The relationship between powder inhaler resistance and peak inspiratory conditions in healthy human volunteers – implications for in vitro testing.
J Aerosol Sci.
1993;
6
99-110
55
Hindle M, Byron P R.
Dose emissions from marketed dry powder inhalers.
Int J Pharmaceut.
1995;
116
169-177
56
Newman S P, Hollingworth A, Clark A R.
Effect of different modes of inhalation on drug delivery from a dry powder inhaler.
Int J Pharm.
1994;
102
127-132
57
Newman S P, Morén F, Trofast E. et al .
Terbutaline sulphate turbohaler: effect of inhaled flow rate on drug deposition and efficacy.
Int J Pharm.
1991;
74
209-213
58
Ross D L, Schultz R K.
Effect of inhalation flow rate on the dosing characteristics of dry powder inhaler (DPI) and metered dose inhaler (MDI) products.
J Aerosol Med.
1996;
9
215-226
59
Beerendonk I van, Mesters I, Mudde A N. et al .
Assessment of the inhalation technique in outpatients with asthma or chronic obstructive pulmonary disease using a metered-dose inhaler or dry powder device.
J Asthma.
1998;
35
273-279
60
Voshaar T H, App E M, Berdel D. et al .
Empfehlungen für die Auswahl von Inhalationssystemen zur Medikamentenverabreichung.
Pneumologie.
2001;
55
579-86
Dr. Thomas H. Voshaar
CA Med. Klinik III, Schwerpunkt Pneumologie, Allergologie, Zentrum für Schlaf- und Beatmungsmedizin, Interdisziplinäres Lungenzentrum, Krankenhaus Bethanien
Bethanienstr. 21
47441 Moers
eMail: th.voshaar@t-online.de